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ABSTRACT
Background. Multiple recent reports have documented
significant variability of reoperation rates after initial
lumpectomy for breast cancer. To address this issue, a mul-
tidisciplinary consensus conference was convened during the
American Society of Breast Surgeons 2015 annual meeting.
Methods. The conference mission statement was to ‘‘reduce
the national reoperation rate in patients undergoing breast
conserving surgery for cancer, without increasing mastectomy
rates or adversely affecting cosmetic outcome, thereby
improving value of care.’’ The goal was to develop a toolbox
of recommendations to reduce the variability of reoperation
rates and improve cosmetic outcomes. Conference partici-
pants included providers from multiple disciplines involved
with breast cancer care, as well as a patient representative.
Updated systematic reviews of the literature and invited
presentations were sent to participants in advance. After topic
presentations, voting occurred for choice of tools, level of
evidence, and strength of recommendation.
Results. The following tools were recommended with
varied levels of evidence and strength of recommendation:
compliance with the SSO-ASTRO Margin Guideline;
needle biopsy for diagnosis before surgical excision of
breast cancer; full-field digital diagnostic mammography
with ultrasound as needed; use of oncoplastic techniques;
image-guided lesion localization; specimen imaging for
nonpalpable cancers; use of specialized techniques for
intraoperative management, including excisional cavity
shave biopsies and intraoperative pathology assessment;
formal pre- and postoperative planning strategies; and
patient-reported outcome measurement.
Conclusions. A practical approach to performance
improvement was used by the American Society of Breast
Surgeons to create a toolbox of options to reduce
lumpectomy reoperations and improve cosmetic outcomes.
A gap in quality of healthcare exists whenever variability
of care coexists with evidence that high performance is
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achievable.1,2 Multiple, recent reports have documented
significant variability of care for oncologic reoperation after
initial lumpectomy for breast cancer.3–6 Rates of reoperation
vary from less than 10 % to more than 50 %. This variability
is not accounted for by patient or disease characteristics.
Therefore, the American Society of Breast Surgeons
(ASBrS) convened a multidisciplinary consensus conference
entitled a ‘‘Collaborative Attempt to Lower Lumpectomy
Reoperation rates’’ (CALLER).
The CALLER conference mission statement was
defined as: ‘‘Reduce the national reoperation rate in
patients undergoing breast-conserving surgery for cancer,
without increasing mastectomy rates or adversely affecting
cosmetic outcome, thereby improving value of care.’’
The purpose of the consensus conference was to develop
a practical toolbox of recommendations to help providers
reduce lumpectomy reoperations to the best achievable level
based on available evidence and expert opinion. The target
goal is not zero, and to attempt this would be expected to
impact cosmetic outcome and lower the breast-conserving
therapy rate. The group identified and considered concurrent
efforts to reduce reoperation variability, including the meta-
analysis that resulted in the SSO-ASTRO margin statement
and an updated systematic review of the literature performed
by the American College of Surgeons for their new
‘‘Operative Standards for Cancer’’ manual.7–9
METHODS
Consensus conference participants included experts in
breast cancer care from multiple disciplines (surgery, radi-
ology, pathology, plastic surgery, and radiation and medical
oncology). A statistician and a patient representative with
patient advocacy experience were included. Participants
with expertise in quality measurement, patient-reported
outcomes, guideline development, and clinical trials were
present. There was diversity across breast surgeon practice
type, including community and academic surgeons.
Toolbox development followed to the extent possible the
standards of the Institute of Medicine for guideline devel-
opment.10 Multiple recent systematic literature reviews were
referenced by participants.7,9,11–21 Before the conference, all
participants were provided with key topics, references,
speaker presentations, and potential ‘‘tools’’ for the toolbox.
After topic presentation, an interactive discussion occurred
followed by voting. Conference participants and the ASBrS
Board of Directors approved toolbox recommendations.
RESULTS
The proposed conference tools, references, level of
evidence, consensus, and strength of recommendation are
described in Tables 1 and 2. Recognizing the impact of
reoperations on patient care, cost, and outcomes, the con-
ference participants had uniform agreement to set a 5-year
target goal for a national average reoperation rate in the
year 2020. However, there was lack of uniformity for the
actual target number. Two-thirds (10/15) of participants
recommended a goal of less than 20 %.
Tool 1: Preoperative Diagnostic Imaging Should
Include Full-Field Digital Mammography and
Supplementary Imaging to Include Ultrasound as
Needed
All participants agreed that high-quality, meticulous, pre-
operative, diagnostic mammography was necessary
preoperatively. ‘‘Selective’’ use of ipsilateral ultrasound (US)
was recommended. US may be of less benefit when screening
mammography identifies calcifications without mass. Despite
near routine actual use of US by conference participants, they
concluded that the level of evidence did not support a rec-
ommendation for ‘‘routine’’ US. Breast tomography was
discussed and judged to have future applications but was not
yet included in the toolbox due to insufficient evidence.
Routine use of MRI was not recommended based on meta-
analyses that show its use does not affect the rate of reexcision
or local recurrence. Selective use of MRI is described in
position statements from other groups.22–24
Tool 2: Minimally Invasive Breast Biopsy (MIBB) for
Breast Cancer Diagnosis
Some studies demonstrate lower reoperation rates when a
diagnosis of malignancy is known before surgical excision.
MIBB provides opportunity for preoperative treatment
planning to include genetic risk assessment, medical oncol-
ogy, and plastic surgery consultation and axillary evaluation.
Tool 3: Multidisciplinary Discussions to Include
Radiology, Pathology, Surgery, and Radiation and
Medical Oncology
Optimizing reoperation rates requires preoperative col-
laboration between radiologists, surgeons, and pathologists.
In patients considered for neoadjuvant therapy, medical
oncology consultation also is necessary. Preoperative
knowledge of number of lesions, geometry, distance to skin
and chest wall, and possible extension towards the nipple
may all facilitate negative margins. Information technology
that enhances communication and provides intraoperative
archived images can aid lesion review and communication.
Postoperative discussion with all specialties aids decision
making regarding reoperation.
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Tool 4: For Nonpalpable Breast Lesions, the Use of
Radioactive Seeds, Intraoperative US, or Wire
Localization to Direct Lesion Excision is Recommended
A localization method should be used for resection of all
nonpalpable cancers. Although some studies have indicated
superiority of one technique compared with another, the
conference concluded that evidence to recommend a single
technique was not definitive. Surgeon use of US also can be
used to aid targeting and decide volume of resection in both
palpable and nonpalpable lesions. Placement of multiple
localizing wires or seeds (bracketing) may be useful for
larger lesions, multifocal tumors, or extensive ductal car-
cinoma in situ (DCIS).
Tool 5: Oncoplastic Techniques can Reduce the Need
for Reoperation in Anatomically Suitable Patients
Oncoplastic techniques have the potential to decrease
positive margins at initial lumpectomy by allowing resec-
tion of a larger volume of tissue. They also may improve
ipsilateral breast appearance and contralateral breast sym-
metry. There was uniform agreement for their potential
benefit. The conference recommends applying these tech-
niques only in a selective group of patients. Small primary
cancers can be excised with acceptable cosmetic results
without oncoplastic techniques. For all procedures, marker
clips or other marking modality should be considered for
application to cavity side walls to aid radiation planning.
Tool 6: Specimen Orientation of 3 or More Margins
When the breast cancer is excised, markers or ink should
be placed on the specimen for orientation to ensure which
margin edge(s) is/are positive to guide focused reexcision
of the correct tissue, if necessary. There are limited data
linking orientation directly to reoperation rates, but the
conference concluded the benefit/burden ratio of orienta-
tion was high. All excisions should be oriented. Orientation
is associated with better cosmetic outcomes by avoiding
‘‘entire cavity’’ reexcision in patients with nonoriented
positive margins. The consensus was that orientation of at
least three sides was superior to two sides. Some partici-
pants favored intraoperative six-sided inking as best
practice, but there was no consensus on orientation
methodology beyond labeling at least three margins.
Tool 7: Specimen Radiograph with Surgeon
Intraoperative Review
The primary role of specimen imaging is to document
removal of the targeted nonpalpable lesion before the
patient leaves the operating room. Lower-level evidence
supports specimen radiography as a method to assess dis-
tance of lesion to margin and therefore direct and
potentially reduce reoperation. Specimens should not
undergo compression during imaging, because it may cause
specimen fracture that allows ink to enter the crevasse and
a false-positive margin. Some participants supplement
specimen radiography with US. Surgeons should review
the specimen imaging before the operation has been com-
pleted, ideally with surgeon-radiology communication.
Real-time review may avoid a complete ‘‘miss’’ of the
lesion or direct the surgeon to perform an additional cavity
shave for a ‘‘close’’ margin. Specimen imaging may not be
universally available. If not, the conference strongly
encourages systems to develop necessary resources for
specimen imaging with immediate image review. Two
views at orthogonal angles may identify close or positive
margins not seen on a single view. Intraoperative imaging
with other modalities to include tomograms, MRI, CT, and
other imaging are being investigated.
Tool 8: Consider Cavity Shave Margins in Patients with
T2 or Greater Tumor Size or TI with Extensive
Intraductal Carcinoma (EIC)
There are moderate levels of evidence that cavity side
wall excisions correlate with lower reoperation rate. Shave
size should provide adequate sampling of the residual wall.
‘‘Tiny shaves’’ representing only a small portion of a
‘‘wall’’ were discouraged. If shaves are performed, the
‘‘final’’ edge should be marked; i.e., nonoriented shave
with even a small amount of tumor on the surface would
constitute a final ink positive margin status requiring
reexcision. Some surgeons routinely perform shaves of all
cavity side walls regardless of tumor type or size. Others
perform selective shaves directed by palpation, imaging, or
pathologic specimen examination. There has been one
recently published, randomized, controlled trial of cavity
shave versus no-shave margins, which demonstrated a
statistically significant decrease in the reoperation rate for
patients undergoing breast conservation surgery.25
Tool 9: Intraoperative Pathology Assessment of
Lumpectomy Margins may Help Decrease Reexcision
When Feasible
A systematic literature review demonstrates that intra-
operative margin assessment with frozen histologic section
or imprint cytology are associated with lower reoperation
rates by allowing intraoperative reexcision of positive
margins.13 There is lower-level evidence to support only
gross specimen examination. Resources and expertise may
limit the feasibility of routine intraoperative pathology
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assessment. Several institutions report low reoperation
rates without intraoperative margin assessment.
Tool 10: Compliance with the SSO-ASTRO Margin
Guideline to Not Routinely Reoperate for Close
Margins with no Tumor on Ink in Patients with Invasive
Cancer
Compliance with this guideline has the potential to
reduce reoperations by 40 %.6 The remaining tools are
targeted towards reducing ink positive margins at the initial
lumpectomy. By meta-analysis, recurrence risk doubles
when ink positive margins are not excised. Recurrence is
not improved by reoperation if the margin is negative. If
ink positive margins occur, the need for reoperation should
be evaluated by the treating team in collaboration with the
patient (‘‘shared decision making’’), providing patients
with recurrence risks in absolute percentages for the
choices of reoperation or not. As a consequence, some
patients may choose not to have reoperation. The margin
guideline is applicable to subsets of patients with ‘‘bad
tumor biology’’ (triple negative, Her 2 positive, high
grade), young age, lobular cancer, EIC, or not receiving
systemic treatment. There is no proven benefit for reoper-
ation in these patients if they have ink negative margins.
Some patients with negative margins may still be consid-
ered for reoperation, if clinical and/or imaging findings
suggest residual persistent adjacent disease. The margin
meta-analysis did not include patients with neoadjuvant
therapy or pure DCIS. Given the lack of consensus
regarding acceptable margin width for DCIS, decisions
regarding reoperation in these patients optimally involves
multidisciplinary input and shared decision making with
the patient. Until new evidence is available for DCIS, the
conference supports NCCN guidelines for reoperation if
the margin is ink positive or\1 mm.26
TABLE 1 CALLER Toolbox to reduce reoperation and improve cosmetic outcomes







SSO-ASTROa guideline 94 % High 2A nonuniform Strong-moderate 7,8,14
Minimally invasive breast biopsy 94 % High 1 nonuniform Strong 12,15,49,50
Complete diagnostic mammography and
US as needed
94 % Lower 2B nonuniform Strong-moderate 11,16,51–54
Oncoplastic lumpectomy 100 % Lower 2A uniform Strong-moderate 17,43–48,55,56
Lesion localization 94 % Lower 2A nonuniform Strong 9,18–20,49,50,53,54,57–86
Specimen orientation 95 % Lower 2A nonuniform Strong 49,50,87,88
Cavity shaves 75 % Lower 2A nonuniform Strong-moderate 25,89–97
Specimen imaging and surgeon review 100 % Lower 2A uniform Strong 50,98–106
Intraoperative pathology 89 % Lower 2A–2B nonuniform Strong-moderate 13,21,27,107–124
Preoperative multidisciplinary planning 100 % Lower 2A uniform Strong-moderate 49,50,125,126
Patient-reported outcome measurement 57 % Lower 2B nonuniform Moderate-weak 127–135
a SSO-ASTRO guideline only applicable for invasive cancer
TABLE 2 Level of evidence/consensus and strength of recommendation categories




4. Moderate to weak
5. Weak
6. Insufficient evidence
1. (1) High-level evidence; uniform CALLER consensus that intervention is appropriate
2. (2A) Lower-level evidence; uniform CALLER consensus that intervention is appropriate
3. (2B) Lower-level evidence; CALLER majority consensus that intervention is appropriate
4. (3) Based on any level evidence; major CALLER disagreement that intervention is appropriate
Level of evidence and consensus scale is adapted from NCCN guidelines
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Tool 11: Routine Breast-Specific Patient Reported
Outcome (PRO) Measurement may Help to Assess
Cosmetic Outcomes When Feasible
There is limited reporting in the literature of cosmetic
and functional outcomes from the patient perspective.
Validated PRO tools, such as BREAST-Q, should be
more widely adopted and may aid improvement. New tools
need to be developed that decrease the burdens for both
providers and patients for reporting.
DISCUSSION
The goal of the consensus conference was to provide
practitioners with a variety of tools that can be adapted to
help lower rates of reoperation following lumpectomy.
While these recommendations are not meant to serve as
guidelines or standard of care, conference leaders complied
with most principles for guideline development as defined
by the IOM.10 Updated systematic reviews were referenced
and the group included multiple disciplines and stake-
holders.7,9,11–21 The group did not provide a period for
public comment, request for other society endorsement, or
commission new systematic literature reviews. For expe-
diency, recommendations were provided that could be
implemented into clinical practice quickly. ‘‘Standard of
care’’ is a legal term, and our toolbox does not establish a
new legal ‘‘standard of care.’’ It also is important to rec-
ognize that performing reoperation does not mean poor
quality care. Particularly, omission of reoperation for
positive margins is not recommended. Reoperation of a
positive margin is good quality care and results in lower
risk of cancer recurrence. All tools in the toolbox earned
endorsement by a majority vote. It does not follow that all
tools are recommended for every patient.
At least three factors should be considered for selection.
The first is resource availability. For example, one tool is
the use of intraoperative frozen section (FS) for margin
assessment, a tool associated with very low rates of reop-
eration.27 This service may not be available in all settings,
and there should be no inference of ‘‘poor quality’’ for lack
of access to it. In contrast, multidisciplinary preoperative
planning—in person or virtual—can be implemented
widely.
The second consideration for tool selection is baseline
reoperation rate. The average reoperation rate in four
national databases ranges from 20 to 24 %.3–6 For surgeons
and institutions with average or higher rates, a trial of
previously unused or underutilized tools should be con-
sidered, followed by tracking of outcomes. For those with
rates already in the best tiers of performance, there can be
attempts to improve even further by testing different or
TABLE 3 Performance tracking options during initiatives to reduce reoperation and improve cosmetic outcome
1. Core needle biopsy rate for cancer diagnosis*
2. Specimen imaging rate*
3. Specimen orientation rate*
4. Rate of ink positive margins at initial lumpectomy
5. Compliance rate with SSO-ASTRO margin statement
6. Reoperation rate after initial lumpectomy for breast cancer*
7. Breast conserving therapy rate
8. Cost/charges per episode of care
9. Patient reported outcomes to include cosmetic outcome after lumpectomy*
10. Ipsilateral breast tumor recurrence rate
* ASBrS endorsed Quality Measure audited in Mastery Program37
TABLE 4 American Society of Breast Surgeon efforts to reduce variability of reoperation rates after initial lumpectomy for cancer
1. Orlando Consensus Conference April 30, 2015
2. Auditing and peer performance comparison of re-excision rates and reasons for re-operation available in the ASBrS Mastery Program6,37
3. Development of formal specifications for a reexcision lumpectomy rate quality measure in 2014
4. Development of a patient reported cosmetic outcome measure in the Mastery patient survey
5. Development of a guideline for the technique of ‘‘breast-conserving surgery’’ available on the ASBrS website
6. Education emphasizing compliance with the SSO-ASTRO margin statement during the 2014 and 2015 annual meetings
7. Quality and Research committees of the ASBrS to begin a prospective, observational study of members to search for associations between
reoperation rates and the CALLER conference tools in 2015. This effort is intended to aid the design of subsequent comparative
effectiveness research
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additional tools, but performance tracking will still be
necessary.
The last consideration for number of tools is ‘‘redun-
dancy.’’ For example, if circumferential lumpectomy FS is
used and negative, then the benefit of additional shaving of
cavity side walls is low. If complete cavity side wall
shavings are performed, then the benefit of lumpectomy
margin FS is low too. Some participants recommended
using more tools when operating on patients with known
factors associated with positive margins, such as larger
size, invasive lobular type, low-grade noncalcified DCIS,
and EIC status. All tools in the toolbox can be applied for
patients with DCIS and invasive cancer except the SSO-
ASTRO margin statement, which was specific for invasive
cancer and did not include patients with pure DCIS.
Intraoperative devices to assess margin status were
discussed as potential tools to decrease reoperation. A
recent, randomized trial concluded that the MarginProbeTM
device was associated with fewer reoperations.28 The
conference majority vote was to omit these devices from
the toolbox until further investigation.28–36
Measurement of both individual surgeon and institutional
outcomes are essential prerequisites during attempts to
reduce reoperation after initial lumpectomy. Measurement
assesses the impact of these initiatives. If resources are
available, a comprehensive audit that tracks intended and
unintended outcomes is recommended (Table 3). If resour-
ces are limited, then minimal tracking would include
reoperation, positive margin, and breast-conserving therapy
(BCT) rates. Reoperation rates and BCT rates can be
reported in the ASBrS Mastery database, the National Con-
sortium of Breast Centers Quality Measurement Program,
and ‘‘in-house’’ registries.37,38 All breast cancer quality-
measurement programs were recently summarized.39
Increased mastectomy rates and poor cosmetic outcomes
are potential unintended adverse outcomes of efforts to
lower reoperation rates and therefore should be moni-
tored.40–42 These risks were recognized but were felt to be
balanced by the potential to improve overall patient care by
following conference recommendations. There is evidence
that both reoperation rate and cosmetic outcome can
improve by adoption of oncoplastic techniques.43–48
The conference process and work product is not without
limitations. We did not follow strict guideline development
standards and did not use a formal Delphi process in
arriving at consensus. Furthermore, most of the tools are
not based on high-level evidence. The strength of the
conference is its recognition that unacceptable variability
occurs in the care of patients undergoing lumpectomy. As a
consequence, multiple stakeholders accepted ownership
and then developed recommendations to improve care,
cost, and outcomes by using ‘‘best available’’ evidence and
expert opinion.
CONCLUSIONS
Recognition of the gap between actual and achievable
care led to development of a toolbox of recommendations
to reduce the proven variability of reoperation and the
suspected variability of cosmetic outcome after initial
lumpectomy for breast cancer. A list of other ASBrS ini-
tiatives to reduce reoperation and improve cosmesis is
described in Table 4. Tracking of outcomes is recom-
mended for all initiatives. Next steps include: (1)
dissemination and implementation strategies; (2) compar-
ative effectiveness research to determine which tools or
collection of tools are most strongly associated with
reoperation rates, cosmetic outcome, and value; and (3)
collaboration with industry, payer, and government stake-
holders to provide better support for performance reporting
that is funded, incentivized, and less burdensome for
providers.
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